Extranodal testicular anaplastic versus plasmablastic plasma cell tumor: A rare case with diagnostic dilemma in a developing country

Martin, Petra; Ramesh, Anita; Hercules, Simon; Silamban,; Thangaswamy, Dhanasekar; Mallikarjuna, V S; Mathew, Lionel Rohit

doi:10.4103/0971-5851.81892

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first presentation in this case was a testis plasmacytoma, this site represent 0, 6% of all MM types [6]. Only 18 cases of testicular EMP were reported and many of this initially presentation progressed to MM within one year [7] or as multiple EMP in 10% of cases [8, 9]. …”

Section: Discussionmentioning

confidence: 99%

Extramedullary plasmocytoma relapsing at differents sites: an unusual presentation

Ahnach¹,

Marouan²,

Rachid³

et al. 2013

Pan Afr Med J

View full text Add to dashboard Cite

Extramedullary plasmacytoma (EMP) is an uncommon plasma cell neoplasm results from plasma cell proliferation and consists of monoclonal plasmacytic infiltration, without bone marrow involvement and any other systemic characteristics of multiple myeloma. EMP accounts for 3% of all plasma cell neoplasms and approximately 80% to 90% of EMP involve submucosa of the upper aerodigestive, while scrotal, dermis and retroperitoneal infiltration are very rare. There are no consensus guidelines for treatment, but EMP is highly radiosensitive, surgery may be considered for some sites, but 11 at 30% can progress in multiple myeloma. We report here an exceptional case of recurrent EMP in much localization. It's about a man 72 years old with initially testicular plasmocytoma who generalized the plasmacytic infiltration after 16 months in skin and progressively in mediastinal and retroperitoneal plasmacytoma, without any medullar and bone involvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Extramedullary plasmocytoma relapsing at differents sites: an unusual presentation

Ahnach¹,

Marouan²,

Rachid³

et al. 2013

Pan Afr Med J

View full text Add to dashboard Cite

show abstract

Anaplastic extraosseous (extramedullary) plasmacytoma in the right nostril

Ramos-Martínez

Lagunas‐Rangel

2020

Revista Española de Patología

View full text Add to dashboard Cite

Anaplastic extramedullary plasmacytoma resistant to novel therapies: a case report

et al. 2023

View full text Add to dashboard Cite

Objectives The treatment of choice for extramedullary plasmacytoma (EMP) is radiotherapy (RT). It is under discussion whether the management of an anaplastic form of EMP requires the addition of systemic therapy. Case presentation We present a case of a 66-year-old male who was diagnosed with anaplastic plasmacytoma of the maxillary sinus. After the exclusion of multiple myeloma, Dara-VMP (daratumumab, bortezomib, melphalan, and prednisolone) regimen was initiated. During the third cycle of Dara-VMP, a progression of the tumor was observed. RT and BRd (bendamustine, dexamethasone, and lenalidomide) regimen were initiated. After 4 cycles of BRd, disease progression was established. KRd (carfilzomib, lenalidomide, and dexamethasone) regimen was initiated. The first cycle of KRd was not completed, as the patient was diagnosed with COVID-19. After the infection, the progression of EMP was observed. Conclusions In this case, the anaplastic EMP was resistant to RT and chemotherapy regimens with novel agents, including a monoclonal antibody, an immunomodulatory drug, and proteasome inhibitors.

show abstract

Extranodal testicular anaplastic versus plasmablastic plasma cell tumor: A rare case with diagnostic dilemma in a developing country

Cited by 3 publications

References 10 publications

Extramedullary plasmocytoma relapsing at differents sites: an unusual presentation

Extramedullary plasmocytoma relapsing at differents sites: an unusual presentation

Anaplastic extraosseous (extramedullary) plasmacytoma in the right nostril

Anaplastic extramedullary plasmacytoma resistant to novel therapies: a case report

Contact Info

Product

Resources

About